A big, fast-growing market — running on paper batch records.
We profiled fifty of Europe’s leading pharma and biotech contract manufacturers — from Lonza and Fareva down to Poland’s emerging cost-competitive cluster — across size, modality, ownership and digital maturity. The market is large and compounding, and the growth is racing into biologics and advanced therapies. But dig into how the work actually runs, and a divide opens up: a handful of leaders have named enterprise-AI programs, while most of the field still reviews batch records page by page. That divide is the story.
01 The market
€36bn today, ~€67bn by 2034
Two independent houses size the European CDMO market within a whisker of each other and agree on the trajectory: roughly 7% a year, nearly doubling over the decade.
European CDMO market size (US$ billions)
| Label | Value |
|---|---|
| 2024 | 35.48US$bn |
| 2026 | 40.65US$bn |
| 2028 | 46.57US$bn |
| 2030 | 53.36US$bn |
| 2032 | 61.14US$bn |
| 2034 | 70.05US$bn |
- €36bn → €67bn. Eight Advisory sizes 2025 at €36bn, growing 7.0% CAGR to €67bn by 2034 — independently corroborating the US$ view.
- ~23% of global. Precedence put the wider European CDMO market at US$42.6bn in 2024, about a quarter of the world total.
- Scale vs growth. Small-molecule consolidators drive revenue; biologics and advanced therapies drive the growth rate.
02 Where the growth is
The money is moving into new modalities
The overall market grows ~7%, but that average hides a wide spread. Advanced therapies compound multiples faster than the small-molecule base that still holds most of the revenue.
Growth by modality (CAGR, %)
- 27.9% CAGR. Cell & gene therapy runs from US$8.07bn (2025) toward US$74bn by 2034 — small base, fastest momentum.
- 15.5% CAGR. Biologics / mAbs — roughly double the overall market — from US$22bn (2024) toward ~US$93bn by 2034.
- 20.6% CAGR. Separately, the 'AI-integrated CDMO process optimization' niche itself is forecast to grow ~20.6% a year — but adoption clusters in the top ~6 global CDMOs.
03 The map
675 sites, concentrated in the west
Manufacturing capacity is geographically dense in Western Europe, with France, Italy and Germany leading on site count — and Central & Eastern Europe emerging as the cost-competitive tier.
CDMO manufacturing sites, leading countries
| Label | Value |
|---|---|
| France | 84 sites |
| Italy | 78 sites |
| Germany | 75 sites |
| Poland | 22 sites |
- France leads on count and is expected to grow fastest; Germany dominates by overall capacity value; Switzerland (Basel) leads on depth and quality.
- Poland: 22 sites — the anchor of an emerging CEE cost-competitive cluster (Poland, Lithuania), the largest single-country operator base in the region.
- 'Most cost competitive.' Rezon Bio's new CEO frames the CEE ambition bluntly — to disrupt the European CDMO landscape on cost.
04 The field, by size
A few giants, a long tail
Revenue is top-heavy: a handful of billion-plus consolidators, then a deep mid-tier and a niche/CEE base. (Figures mix reported currencies; some are global, not Europe-only — read as scale, not a like-for-like league table.)
Revenue of leading CDMOs (bn, reported currency)
6
Tier 1 CDMOs above €1bn revenue
Lonza, Catalent, Fareva, Siegfried, Almac, EUROAPI.
6+
Tier 2 between €250m and €1bn
Recipharm, Delpharm, CordenPharma, Rentschler, Meribel, NextPharma.
20+
Tier 3 / niche & Polish players below €250m
Where digital maturity is thinnest — and the opportunity densest.
05 The divide
Only about 1 in 9 has gone truly digital
Across the profiled field, named enterprise digital/AI programs are the exception, not the rule. Most players — especially the mid-tier and CEE — still run paper batch records and siloed LIMS/MES/ERP.
Digital maturity across ~36 profiled CDMOs
- Leaders. Lonza (Nexus SAP S/4HANA + AI/ML), Recipharm (AI-in-PAT, Gates-funded), Rentschler (Global Head of Digital Manufacturing), Boehringer (AI-built Vienna plant).
- The middle. General digitalization and capex language — Siegfried, Almac, Vetter, AGC, Celonic — but no named AI roadmap.
- The laggards. Most mid-size and virtually all Polish CDMOs discuss QbD/cGMP but publish little on MES/LIMS integration or AI — consistent with paper-based operations.
06 Who owns the field
Private equity is the M&A engine
Ownership shapes the digitization appetite: PE roll-ups reward EBITDA-accretive digital wins, while family- and pharma-owned houses move to their own clocks. The mix across the sample is strikingly even.
Ownership structure across the profiled sample
- PE roll-ups are the dominant deal engine — Recipharm (EQT), Adragos (FSN), Meribel (Blue Wolf), Cambrex (Permira), Sterling & Ardena (GHO) — buying and integrating multi-site groups.
- Strategic / pharma-owned captives — Boehringer, Fujifilm Diosynth, AGC, Wacker, IDT — plus Catalent, taken private by Novo Holdings for US$16.5bn.
- Family & public the rest — Fareva, Vetter, Rentschler, Aenova; and the Warsaw- and Western-Europe-listed names, including much of the Polish cluster.
07 The whitespace
Big revenue, low digital maturity — that's the target
Plot the field by digital maturity against revenue and the opportunity pops out: cash-generative manufacturers that still run on paper, plus the entire CEE cluster. Bubble size scales with revenue.
Digital maturity × revenue
- Fastest payback: large, cash-generative makers still on paper — Fareva, Delpharm, Adamed — where digitization lifts utilization and yield.
- Home advantage: the Polish cluster — Mabion, Rezon Bio, Selvita — low maturity, geographically adjacent, acute paper-batch pain.
- Already-mature: Lonza, Recipharm, Rentschler need governance and agents, not their first eBR.
Poland — the emerging cost-competitive cluster
The largest single-country operator base in Central-Eastern Europe, specialized city by city — and, on the public record, among the least digitally mature.
39
CDMO/biotech operators across Poland
22 manufacturing sites — the CEE anchor.
June 2025
Polpharma Biologics demerger
CDMO business becomes Rezon Bio (Gdańsk, Duchnice), positioned to compete on cost.
Top 8
Bioton among the world's recombinant-insulin makers
A globally relevant manufacturer running on legacy digital foundations.
Warsaw
Commercial / manufacturing anchor
Polpharma group, Bioton (insulin), Polfa Tarchomin (state-owned), Adamed.
Gdańsk · Łódź · Kraków
Biologics & CRO
Rezon Bio (biologics CDMO), Mabion (Novavax anchor), Selvita (CRO + PozLab CDMO).
Skawina · Wrocław
Next-gen & home turf
SyVento (first Cytiva FlexFactory in Poland, mRNA/LNP) — and A4BEE's own Wrocław base.
09 Where the pain concentrates
The same five pains, felt hardest in the mid-tier
Aggregate the pain points across the field and they cluster on operations — paper records, data silos, disconnected instruments. Tier-1 leaders feel them less; the mid-tier and CEE feel them most.
Pain-point intensity (0–100)
- 20–40% of scientist time is lost to manual re-typing where instruments aren't connected — pure recoverable capacity.
- Data silos everywhere. ERP, MES, SCADA and LIMS each hold a fragment of the truth; no single source across most Tier 2/3 groups.
- AI pilots stall not for lack of ambition but for lack of governed, AI-ready data underneath them.
Every pain point maps to a play
The sector's dominant pains line up cleanly against a staged digital path — start where the return is clearest, prove it, then climb toward governed AI and agents.
Paper batch records → eBR / MES
Mid-tier & Polish players
Electronic batch records with review-by-exception; live eBR in weeks kills the page-by-page QP release bottleneck.
Siloed ERP/MES/SCADA → data platform
Multi-site PE roll-ups
One governed data foundation unifies acquired sites — the textbook integration play for buy-and-build groups.
Disconnected instruments → connected lab
QC & analytical labs
Instrument connectivity and ELN/LIMS recover the 20–40% of scientist time lost to manual transcription.
GxP & EU AI Act → AI-Ops governance
All EU CDMOs adopting AI
Lineage, access control and Annex 11 / GAMP-5 data integrity make AI auditable — often the buying trigger itself.
Stalled pilots → governed data + RAG
Ambitious mid-tier
A data-and-AI readiness baseline turns messy data into a foundation pilots can actually scale on.
Manual MES/LIMS/QMS work → agents
Digitally mature leaders
Production-grade agents with named human-approval points and full audit trails automate the work that remains.
11 The bottom line
The gap is the market
A large market, compounding at 7%, with growth racing into modalities where capacity is tightest — and a field where most players haven't digitized the shop floor. The winners will be those who close the operational gap first.
~89%
of profiled CDMOs lack a named enterprise AI program
The addressable field, not the exception.
€36bn → €67bn
market nearly doubling by 2034
At ~7% CAGR, with biologics and CGT far faster.
Poland
the cost-competitive cluster on A4BEE's doorstep
Low maturity, acute pain, home advantage.
Close the operational gap first — digitize the shop floor with A4BEE.